Angiogenesis & Metastasis Flashcards
Define Angiogenesis
<b>The formation of new blood vessels</b><span>. This process involves the migration, growth, and differentiation of endothelial cells, which line the inside wall of blood vessels.<br></br>This is a common process in solid tumors in order to allow expansion and nutrient availability.<br></br></span>Restriction of this vasculature causes tumor regression.<br></br>Angiogenesis also provides avenues for metastasis, which is dependent on tumor cell travelling via vasculature.
Erythropoietin (Epo)
NAME?
Hypoxia Inducible Factor (HIF)
- TFs (helix-loop-helix structure) that binds to the Epo promoter for expression<br></br>- Heterodimers with an alpha + beta subunit<br></br>- Binds to the HRE (hypoxia response element) with the CGTG core sequence<br></br>- In normoxic conditions, HIF is rapidly degrad
Von Hippel-Lindau Syndrome
NAME?
VHL Structure
<br></br><img></img><br></br>- 29kDa<br></br>- B domain binds directly to HIF<br></br>- Cancer associated mutations occur in B domain<br></br>- a domain has a region of homology to Skp2<br></br>- Enables VHL to contact ubiquitin ligase machinery (Elo B/C and Cullin 2)<br></br>- This complex acts as a ubiquitin ligase with VHL acting as the adaptor subunit connect HIF to ligase
Hypoxia and HIF Fate
NAME?
Oxygen Sensing
- Prolyl 4-hydroxylase enzyme hydroxylates prolines using a-ketoglutarate (abundant in oxygen based metabolism) and molecular oxygen<br></br>- Direct sensing of oxygen levels by this enzyme<br></br>- HIF is a substrate for prolyl 4-hydroxylase (proline 402/564)<br></br>
HIF Targets
- Glycolytic isozymes<br></br>2. Erythropoietin<br></br>2. Vascular endothelial growth factor
HIF & Glycolytic Isozymes
- Tumors usually preferentially use glycolysis for ATP generation due to their hypoxic conditions<br></br>- HIF upregulates hexokinase, phosphofructokinase, & pyruvate kinase, which are the three rate limiting enzymes of glycolysis
HIF & Vascular Endothelial Growth Factor
- Secreted into the environment acting on surrounding cells<br></br>- Homodimeric secreted hormone<br></br>- Causes increased vascularization and increased vascular permeability<br></br>- Endothelial cells have VEGF receptors on cell surface
VEGF Receptor
- Receptor tyrosine kinase<br></br>- Ligand binding leads to dimerization and trans-auto phosphorylation<br></br>- Downstream signalling targets include, Ras/MAPK/PI3K<br></br><br></br><img></img>
VEGFR Family
- VEGFR-1: vascular permeability<br></br>2. VEGFR-2: vascularization<br></br>3. VEGFR-3: lymphangiogenesis
Overview of Angiogenesis
NAME?
Avastin
- Anti-VEGF antibody<br></br>- Prevent extracellular ligand binding and therefore intracellular effects<br></br>- However, there is only ~5 months of increased survival which is not very effective
Sorafenib/Sunitinib
- Tyrosine kinase inhibitors towards VEGFR<br></br>- However, we have 514 protein kinases with conserved fold and ATP binding site<br></br>- Difficult to make VEGFR inhibitors that are not pan-reactive with off-target effects